ScholarIQanswers from OpenAlex
Japan Society for the Promotion of Science
FunderResearch funding and supported work
Japan Society for the Promotion of Science is a funder indexed in ScholarIQ from OpenAlex.
What is known about Japan Society for the Promotion of Science?
ScholarIQrecord summary
administrative agency in Japan
How many works does Japan Society for the Promotion of Science have?
ScholarIQindexed works
Japan Society for the Promotion of Science has 1,012,869 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Japan Society for the Promotion of Science?
ScholarIQopenalex
The OpenAlex for Japan Society for the Promotion of Science is on the source record.
What is the ROR of Japan Society for the Promotion of Science?
ScholarIQror
The ROR for Japan Society for the Promotion of Science is on the source record.
What are the most-cited papers on Japan Society for the Promotion of Science?
ScholarIQmost cited works
Proceedings of the National Academy of Sciences
C.B. Walker, J.R. De la Torre, M.G. Klotz, H. Urakawa, N. Pinel, D. J. Arp, C. Brochier-Armanet, P. S. G. Chain, PK Chan, A. Gollabgir, J. Hemp, Michael Hügler, E.A. Karr, M. Könneke, M. Shin, T.J. Lawton, T. Lowe, W. Martens-Habbena, L.A. Sayavedra-Soto, D. Lang, S. M. Sievert, A.C. Rosenzweig, G. Manning, D.A. Stahl
Polycystic kidney disease
Carsten Bergmann, Lisa M. Guay‐Woodford, Peter C. Harris, Shigeo Horie, Dorien J.M. Peters, Vicente E. Torres
The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD
Hisanori Umehara, Kazuichi Okazaki, Shigeyuki Kawa, Hiroki Takahashi, Hiroshi Gotô, Shoko Matsui, Nobukazu Ishizaka, Takashi Akamizu, Yasuharu Sato, Mitsuhiro Kawano
Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD
Niels Jongs, Glenn M. Chertow, Tom Greene, John J.V. McMurray, Anna Maria Langkilde, Ricardo Correa‐Rotter, Naoki Kashihara, Peter Rossing, C. David Sjöström, Bergur V. Stefánsson, Robert D. Toto, David C. Wheeler, Hiddo J.L. Heerspink
Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS Clinical Trial
Yuzuru Kanakura, Kazuma Ohyashiki, Tsutomu Shichishima, Shinichiro Okamoto, Kiyoshi Ando, Haruhiko Ninomiya, Tatsuya Kawaguchi, Shinji Nakao, Hideki Nakakuma, J Nishimura, Taroh Kinoshita, Camille L. Bedrosian, Marye Ellen Valentine, Gus Khursigara, Keiya Ozawa, Mitsuhiro Omine